Regeneron Pharmaceuticals forward PE REGN

Share price divided by analysts' consensus earnings for the next twelve months, since 2011.

Today, Oct 23, 2026: 12.6×
10-year median: 17.4×
Against its 10-year history: 17th; percentile: 0 is its lowest day, 100 its highest
10-year range: 7.9× to 35.1×
Peer median: 27.0×

Regeneron Pharmaceuticals' forward PE is 12.6× as of Oct 23, 2026.

That is below its ten-year median of 17.4×, lower than on 83% of days in the last ten years.

Over that time it ranged from 7.9× in Feb 2021 to 35.1× in Jun 2017.

The median for 10 biotech stocks of a similar size is 27.0×.

Forward PE over time

median 17.4×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	12.6×	10.4×	17.4×
2025	17.1×	13.0×	19.0×
2024	18.8×	18.5×	30.0×
2023	20.3×	16.7×	20.3×
2022	17.9×	12.4×	19.3×
2021	13.0×	7.9×	13.8×
2020	10.7×	10.6×	21.5×
2019	14.4×	10.8×	18.8×
2018	15.8×	14.9×	23.8×
2017	23.2×	23.1×	35.1×
2016	28.0×	28.0×	43.7×
2015	48.3×	33.7×	51.5×
2014	37.9×	27.6×	39.2×
2013	34.8×	33.8×	64.6×
2012	42.0×	34.6×	309×
2011	168×	151×	177×

Against its peers

Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.

Company	Forward PE
REGNRegeneron Pharmaceuticals	12.6×
VRTXVertex Pharmaceuticals	27.0×
ONCBeOne Medicines	48.1×
ALNYAlnylam Pharmaceuticals	26.7×
UTHRUnited Therapeutics	22.0×
INCYIncyte	49.5×
EXELExelixis	n/m
NBIXNeurocrine Biosciences	n/m
HALOHalozyme Therapeutics	n/m
TECHBIO-TECHNE	n/m
RGENRepligen	n/m
Peer median	27.0×

Where Regeneron Pharmaceuticals ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Regeneron Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.